Developer docs
API playgroundTry for free, no card

Search company profiles

Foresee Biosystems

Full company profile

uuid002gi32

Namestring
Foresee Biosystems
Legal namestring
Foresee Biosystems S.r.l.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Foresee Biosystems S.r.l. is a privately-held Italian biotech instrumentation company incorporated in 2021 as a spin-off of the Italian Institute of Technology (IIT) in Genoa. The company develops platforms for predicting the toxicological outcomes of drugs and chemicals on cellular models, with a current focus on in-vitro cardiotoxicity assessment for pharmaceutical and academic research customers.

The core product, IntraCell, is a laser-based platform that combines Foresee's patented optoporation technology with Multi Channel Systems (MCS) microelectrode array (MEA) hardware. Optoporation uses laser-induced optoacoustic waves to create localized nanopores in cell membranes, enabling transition from extracellular to intracellular recording without compromising cellular viability. The platform records action potentials from thousands of cardiomyocytes simultaneously over periods up to approximately 45 days, making it the first electrophysiological tool designed specifically for chronic cardiotoxicity assessment. Software add-ons include FB_Alps 1.0 (automated assay setup, optical visualization, laser auto-focus and auto-alignment) and the Action Potential Profiler (automated extraction of electrophysiological parameters), launched in 2024.

Commercially, Foresee operates a hybrid revenue model: capital equipment sales (IntraCell hardware plus software), trial and measurement services where customers send compounds to the Genoa laboratories, and non-dilutive European research grants. Global distribution is delivered through a partnership with Harvard Bioscience covering Europe, Africa, Asia, and the USA, with direct sales from the Genoa headquarters for the Italian market. Target segments are pharmaceutical and biotech drug-safety teams, academic and research institutions (with named users including the Universities of Parma, Verona, and La Sapienza), and contract research organizations, supported by publications in journals such as Nature Nanotechnology, Science Advances, and Archives of Toxicology. The company is led by co-founder and Chairman-CEO Michele Dipalo and CTO Giulia Bruno, with a scientific advisory board that includes co-founders of MCS GmbH.

Short descriptiontext

Foresee Biosystems is an Italian IIT spin-off that sells laser-based optoporation instruments and software for chronic in-vitro cardiotoxicity electrophysiology assessment, serving pharmaceutical, academic, and CRO customers via its IntraCell platform and Harvard Bioscience distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGenova, Italy
HQ citystring
Genova
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiotoxicity assessment, electrophysiology platforms, drug safety testing, microelectrode arrays, laser optoporation
Industry2 codes
PRIMARYHLAGAAAJ
Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Research and Development in Nanotechnology541713
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Laboratory Analytical Instruments3826
Product category
Drug Safety Testing Equipment
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1IntraCell Hardware System Sales
TypeHardware Sales
Description

Sale of IntraCell laser-based systems for electrophysiological recording, including system hardware and associated software packages.

foreseebiosystems.com
2Trial and Testing Services
TypeProfessional Services
Description

Offering trial services to test the system and demonstrate capabilities in detecting acute and chronic cardiotoxicity. Customers send compounds to company laboratories for measurement services.

foreseebiosystems.com
3European Research Grants
TypeSubscription Recurring
Description

Non-dilutive funding from European Innovation Council grants for specific research projects including SiMulTox, TwistedNano, and Chronos.

foreseebiosystems.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1IntraCell
Description

Laser-based platform for in-vitro cardiac electrophysiology enabling long-term action potential recordings from cardiomyocytes for acute and chronic cardiotoxicity assessment.

foreseebiosystems.com
+2 more records
Core offering1 text field

Foresee Biosystems develops and manufactures the IntraCell platform, a laser-based optoporation system integrated with multi-electrode array (MEA) technology for chronic in-vitro cardiotoxicity assessment. The platform enables pharmaceutical, biotech, academic, and CRO customers to perform long-term cardiac electrophysiology testing on the same cell samples non-invasively, addressing a critical preclinical drug safety evaluation need.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Action potential recordings from same cells up to 45 days (chronic cardiotoxicity assessment)
+3 more records
Product overview1 text field

Foresee Biosystems is a biotech startup developing innovative solutions for in-vitro cardiotoxicity assessment based on a patented LASER-based technology. The product portfolio consists of IntraCell as the core hardware platform, supplemented by two software add-ons: FB_Alps 1.0 for automated assay setup, optical visualization, and laser control, and Action Potential Profiler for automated action potential data analysis. Together, these products enable simultaneous recordings of action potentials from thousands of cardiomyocytes, with the ability to record from the same cells for up to one month, representing the first electrophysiological tool for chronic cardiotoxicity assessment.

Product and service2 records
1IntraCell
CategoryDrug Safety Testing Equipment
Description

IntraCell is a laser-based optoporation platform integrated with Multi Channel Systems microelectrode array (MEA) technology, designed for chronic in-vitro cardiotoxicity assessment. It enables pharmaceutical, biotech, academic, and CRO customers to perform non-invasive, repeated electrophysiology measurements on the same cardiac cell samples over extended periods, addressing a critical gap in preclinical drug safety testing.

2Trial and Testing Services
CategoryContract Research Services
Description

Service-based offering where Foresee Biosystems performs trial and testing engagements using the IntraCell platform on behalf of pharmaceutical, biotech, academic, and CRO customers. Provides an entry point for customers evaluating the technology before purchasing the full hardware system.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Foresee Biosystems originated as a spinout from IIT in 2021. The company's foundational technology was developed through IIT research programs including NEURO-PLASMONIC (Ideas-ERC project, 2014-2018) and MAREP (2019).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Harvard Bioscience serves as the primary distribution partner for Foresee Biosystems, covering Europe & Africa (contact: Jörgen Nööjd, Senior Director) and USA (contact: Ryan Gilbert, Sales Manager) markets, as well as Asia distribution.

Strategic tierCoreTypeTechnology or Integration
Description

MCS provides the microelectrode array (MEA) hardware platforms (60, 120, 256 electrodes single and multiwell systems) that Foresee Biosystems integrates its laser technology with for the IntraCell system.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Charles River is a major preclinical CRO with extensive cardiac safety assessment services. It represents the incumbent outsourced alternative that Foresee's pharma customers may use instead of, or alongside, in-house IntraCell-based workflows.

TypeEmerging player
Description

TissUse develops multi-organ-chip and microphysiological systems for toxicology testing, including cardiac applications. It is comparable as an emerging organ-on-chip player whose chronic and multi-organ toxicity workflows overlap with Foresee's longer-term safety thesis.

3CN Bio Innovations
TypeEmerging player
Description

CN Bio offers single- and multi-organ organ-on-chip platforms, including cardiac applications, for drug safety and efficacy testing. It is comparable as a higher-throughput in vitro safety technology that competes for the same pharma in vitro safety budgets.

TypeEmerging player
Description

Emulate's organ-on-chip platform is used for cardiac and other organ toxicity testing. It is comparable as an emerging in vitro alternative for preclinical safety, and overlaps with Foresee's cardiac organoid / organ-on-chip use cases at academic customers.

TypeDirect peer
Description

Nanion supplies automated patch clamp and electrophysiology instrumentation (e.g., Port-a-Patch, SyncroPatch) used in cardiac safety and CiPA workflows. It competes for the same pharma safety budgets with complementary rather than identical technology.

TypeBroad incumbent
Description

MCS is Foresee's hardware platform partner and the established incumbent in MEA recording systems. It is comparable because customers evaluating IntraCell are typically already MCS MEA users, and any vertical integration by MCS would directly overlap Foresee's integrated value proposition.

TypeDirect peer
Description

Axion sells MEA-based platforms (Maestro) for electrophysiology and cardiotoxicity screening. It competes with Foresee in the MEA electrophysiology workflow used by pharma and academic cardiac safety labs, and is the most direct platform peer for the recording hardware layer.

TypeDirect peer
Description

Ncardia develops iPSC-derived cardiomyocytes and offers cardiac safety/cardiotoxicity assay services to pharma. It is the closest commercial analogue to Foresee because it targets the same pharmaceutical buyer with predictive in vitro cardiac safety data, even though it sells cellular models and services rather than hardware.

TypeDirect peer
Description

Sophion (now part of B'SYS / Sophion group) provides automated patch clamp platforms for cardiac ion channel safety screening. It targets the same pharmaceutical cardiac safety use cases that Foresee's chronic cardiotoxicity platform addresses, with overlapping customer relationships.

TypeBroad incumbent
Description

Eurofins Discovery offers broad in vitro safety and cardiac safety pharmacology services to pharma, including cardiotoxicity panels. It is comparable as an established commercial alternative for outsourced cardiac safety testing that Foresee positions against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Foresee Biosystems

Drug Safety Testing Equipmentforeseebiosystems.com

Foresee Biosystems is an Italian IIT spin-off that sells laser-based optoporation instruments and software for chronic in-vitro cardiotoxicity electrophysiology assessment, serving pharmaceutical, academic, and CRO customers via its IntraCell platform and Harvard Bioscience distribution.

What Foresee Biosystems does

Foresee Biosystems S.r.l. is a privately-held Italian biotech instrumentation company incorporated in 2021 as a spin-off of the Italian Institute of Technology (IIT) in Genoa. The company develops platforms for predicting the toxicological outcomes of drugs and chemicals on cellular models, with a current focus on in-vitro cardiotoxicity assessment for pharmaceutical and academic research customers.

The core product, IntraCell, is a laser-based platform that combines Foresee's patented optoporation technology with Multi Channel Systems (MCS) microelectrode array (MEA) hardware. Optoporation uses laser-induced optoacoustic waves to create localized nanopores in cell membranes, enabling transition from extracellular to intracellular recording without compromising cellular viability. The platform records action potentials from thousands of cardiomyocytes simultaneously over periods up to approximately 45 days, making it the first electrophysiological tool designed specifically for chronic cardiotoxicity assessment. Software add-ons include FB_Alps 1.0 (automated assay setup, optical visualization, laser auto-focus and auto-alignment) and the Action Potential Profiler (automated extraction of electrophysiological parameters), launched in 2024.

Commercially, Foresee operates a hybrid revenue model: capital equipment sales (IntraCell hardware plus software), trial and measurement services where customers send compounds to the Genoa laboratories, and non-dilutive European research grants. Global distribution is delivered through a partnership with Harvard Bioscience covering Europe, Africa, Asia, and the USA, with direct sales from the Genoa headquarters for the Italian market. Target segments are pharmaceutical and biotech drug-safety teams, academic and research institutions (with named users including the Universities of Parma, Verona, and La Sapienza), and contract research organizations, supported by publications in journals such as Nature Nanotechnology, Science Advances, and Archives of Toxicology. The company is led by co-founder and Chairman-CEO Michele Dipalo and CTO Giulia Bruno, with a scientific advisory board that includes co-founders of MCS GmbH.

Foresee Biosystems firmographics

Firmographics
Name
Foresee Biosystems
Legal name
Foresee Biosystems S.r.l.
Website
https://foreseebiosystems.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Foresee Biosystems is an Italian IIT spin-off that sells laser-based optoporation instruments and software for chronic in-vitro cardiotoxicity electrophysiology assessment, serving pharmaceutical, academic, and CRO customers via its IntraCell platform and Harvard Bioscience distribution.
Ownership category
akta.pro rank

Foresee Biosystems industry classification

Industry
Product category
Drug Safety Testing Equipment
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Nanotechnology (541713)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAAAJ
Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Cardiotoxicity assessment
  • Electrophysiology platforms
  • Drug safety testing
  • Microelectrode arrays
  • Laser optoporation

Where Foresee Biosystems is headquartered

Location

Headquarters

HQ city
Genova
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

Foresee Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. IntraCell Hardware System Sales: Sale of IntraCell laser-based systems for electrophysiological recording, including system hardware and associated software packages.
  2. Trial and Testing Services: Offering trial services to test the system and demonstrate capabilities in detecting acute and chronic cardiotoxicity. Customers send compounds to company laboratories for measurement services.
  3. European Research Grants: Non-dilutive funding from European Innovation Council grants for specific research projects including SiMulTox, TwistedNano, and Chronos.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Foresee Biosystems product offering

Product offering

Core offering

Foresee Biosystems develops and manufactures the IntraCell platform, a laser-based optoporation system integrated with multi-electrode array (MEA) technology for chronic in-vitro cardiotoxicity assessment. The platform enables pharmaceutical, biotech, academic, and CRO customers to perform long-term cardiac electrophysiology testing on the same cell samples non-invasively, addressing a critical preclinical drug safety evaluation need.

Product overview

Foresee Biosystems is a biotech startup developing innovative solutions for in-vitro cardiotoxicity assessment based on a patented LASER-based technology. The product portfolio consists of IntraCell as the core hardware platform, supplemented by two software add-ons: FB_Alps 1.0 for automated assay setup, optical visualization, and laser control, and Action Potential Profiler for automated action potential data analysis. Together, these products enable simultaneous recordings of action potentials from thousands of cardiomyocytes, with the ability to record from the same cells for up to one month, representing the first electrophysiological tool for chronic cardiotoxicity assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • IntraCell: Laser-based platform for in-vitro cardiac electrophysiology enabling long-term action potential recordings from cardiomyocytes for acute and chronic cardiotoxicity assessment.
  • FB_Alps
  • Action Potential Profiler (APP)

Products and services

  • IntraCell IntraCell is a laser-based optoporation platform integrated with Multi Channel Systems microelectrode array (MEA) technology, designed for chronic in-vitro cardiotoxicity assessment. It enables pharmaceutical, biotech, academic, and CRO customers to perform non-invasive, repeated electrophysiology measurements on the same cardiac cell samples over extended periods, addressing a critical gap in preclinical drug safety testing.
  • Trial and Testing Services Service-based offering where Foresee Biosystems performs trial and testing engagements using the IntraCell platform on behalf of pharmaceutical, biotech, academic, and CRO customers. Provides an entry point for customers evaluating the technology before purchasing the full hardware system.

Quantifiable outcome

  • Action potential recordings from same cells up to 45 days (chronic cardiotoxicity assessment)
  • +3 more outcomes

Companies that use Foresee Biosystems

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Foresee Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Foresee Biosystems partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Italian Institute of Technology (IIT)coreStrategic or Co-development Partner · 1 January 2014Foresee Biosystems originated as a spinout from IIT in 2021. The company's foundational technology was developed through IIT research programs including NEURO-PLASMONIC (Ideas-ERC project, 2014-2018) and MAREP (2019).
  • Harvard BiosciencecoreChannel Partner/ Reseller/ DistributorHarvard Bioscience serves as the primary distribution partner for Foresee Biosystems, covering Europe & Africa (contact: Jörgen Nööjd, Senior Director) and USA (contact: Ryan Gilbert, Sales Manager) markets, as well as Asia distribution.
  • Multi Channel Systems (MCS) GmbHcoreTechnology or IntegrationMCS provides the microelectrode array (MEA) hardware platforms (60, 120, 256 electrodes single and multiwell systems) that Foresee Biosystems integrates its laser technology with for the IntraCell system.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Foresee Biosystems competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Charles River is a major preclinical CRO with extensive cardiac safety assessment services. It represents the incumbent outsourced alternative that Foresee's pharma customers may use instead of, or alongside, in-house IntraCell-based workflows.
  • Multi Channel Systems (MCS): MCS is Foresee's hardware platform partner and the established incumbent in MEA recording systems. It is comparable because customers evaluating IntraCell are typically already MCS MEA users, and any vertical integration by MCS would directly overlap Foresee's integrated value proposition.
  • Eurofins Discovery: Eurofins Discovery offers broad in vitro safety and cardiac safety pharmacology services to pharma, including cardiotoxicity panels. It is comparable as an established commercial alternative for outsourced cardiac safety testing that Foresee positions against.

Emerging players

  • TissUse: TissUse develops multi-organ-chip and microphysiological systems for toxicology testing, including cardiac applications. It is comparable as an emerging organ-on-chip player whose chronic and multi-organ toxicity workflows overlap with Foresee's longer-term safety thesis.
  • CN Bio Innovations: CN Bio offers single- and multi-organ organ-on-chip platforms, including cardiac applications, for drug safety and efficacy testing. It is comparable as a higher-throughput in vitro safety technology that competes for the same pharma in vitro safety budgets.
  • Emulate Inc. Emulate's organ-on-chip platform is used for cardiac and other organ toxicity testing. It is comparable as an emerging in vitro alternative for preclinical safety, and overlaps with Foresee's cardiac organoid / organ-on-chip use cases at academic customers.

Direct peers

  • Nanion Technologies: Nanion supplies automated patch clamp and electrophysiology instrumentation (e.g., Port-a-Patch, SyncroPatch) used in cardiac safety and CiPA workflows. It competes for the same pharma safety budgets with complementary rather than identical technology.
  • Axion Biosystems: Axion sells MEA-based platforms (Maestro) for electrophysiology and cardiotoxicity screening. It competes with Foresee in the MEA electrophysiology workflow used by pharma and academic cardiac safety labs, and is the most direct platform peer for the recording hardware layer.
  • Ncardia: Ncardia develops iPSC-derived cardiomyocytes and offers cardiac safety/cardiotoxicity assay services to pharma. It is the closest commercial analogue to Foresee because it targets the same pharmaceutical buyer with predictive in vitro cardiac safety data, even though it sells cellular models and services rather than hardware.
  • Sophion Bioscience: Sophion (now part of B'SYS / Sophion group) provides automated patch clamp platforms for cardiac ion channel safety screening. It targets the same pharmaceutical cardiac safety use cases that Foresee's chronic cardiotoxicity platform addresses, with overlapping customer relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Foresee Biosystems social profiles

Digital presence

Foresee Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Foresee Biosystems leadership team

Management profile

Number of profiles

Profiles2 records

Foresee Biosystems funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Foresee Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foresee Biosystems

What does Foresee Biosystems do?

Foresee Biosystems develops and manufactures the IntraCell platform, a laser-based optoporation system integrated with multi-electrode array (MEA) technology for chronic in-vitro cardiotoxicity assessment. The platform enables pharmaceutical, biotech, academic, and CRO customers to perform long-term cardiac electrophysiology testing on the same cell samples non-invasively, addressing a critical preclinical drug safety evaluation need.

Is Foresee Biosystems a public or private company?

Foresee Biosystems is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Foresee Biosystems founded?

Foresee Biosystems was founded in 2021. It employs 1 to 10 people.

Where is Foresee Biosystems based?

Foresee Biosystems is headquartered in Genova, Italy, in the Europe region.

How does Foresee Biosystems make money?

Three revenue lines are on record. IntraCell Hardware System Sales are the primary driver. The others are trial and Testing Services and european Research Grants.

Who are Foresee Biosystems's main competitors?

Broad incumbents on record are Charles River Laboratories, Multi Channel Systems (MCS) and Eurofins Discovery. Emerging players are TissUse, CN Bio Innovations and Emulate Inc.. Direct peers are Nanion Technologies, Axion Biosystems, Ncardia and Sophion Bioscience.

Does Foresee Biosystems have an API?

No public API is recorded for Foresee Biosystems.

What industry is Foresee Biosystems in?

Foresee Biosystems's product category is Drug Safety Testing Equipment. Its primary akta.pro industry code is HLAGAAAJ, Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales